Skip to main content

Advertisement

Articles

Page 3 of 97

  1. The benefits of chemotherapy in node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with the 21-gene recurrence score (RS) of 18–30, pa...

    Authors: Seho Park, Yunan Han, Ying Liu, Adetunji T. Toriola, Lindsay L. Peterson, Graham A. Colditz, Seung Il Kim, Young Up Cho, Byeong-Woo Park and Yikyung Park

    Citation: Breast Cancer Research 2019 21:110

    Content type: Research article

    Published on:

  2. Bone morphogenetic proteins (BMPs) have been reported to maintain epithelial integrity and to antagonize the transforming growth factor β (TGFβ)-induced epithelial to mesenchymal transition. The expression of ...

    Authors: Jiang Ren, Marcel Smid, Josephine Iaria, Daniela C. F. Salvatori, Hans van Dam, Hong Jian Zhu, John W. M. Martens and Peter ten Dijke

    Citation: Breast Cancer Research 2019 21:109

    Content type: Research article

    Published on:

  3. The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely addressed.

    Authors: Barbara Adamo, Meritxell Bellet, Laia Paré, Tomás Pascual, Maria Vidal, José A. Pérez Fidalgo, Salvador Blanch, Noelia Martinez, Laura Murillo, Patricia Gómez-Pardo, Ana López-González, Kepa Amillano, Jordi Canes, Patricia Galván, Blanca González-Farré, Xavier González…

    Citation: Breast Cancer Research 2019 21:108

    Content type: Research article

    Published on:

  4. The introduction of next-generation sequencing has resulted in testing multiple genes simultaneously to identify inherited pathogenic variants (PVs) in cancer susceptibility genes. PVs with low minor allele fr...

    Authors: Felipe Batalini, Ellie G. Peacock, Lindsey Stobie, Alison Robertson, Judy Garber, Jeffrey N. Weitzel and Nadine M. Tung

    Citation: Breast Cancer Research 2019 21:107

    Content type: Review

    Published on:

  5. To evaluate the diagnostic performance of radiomic signatures extracted from contrast-enhanced magnetic resonance imaging (CE-MRI) for the assessment of breast cancer receptor status and molecular subtypes.

    Authors: Doris Leithner, Joao V. Horvat, Maria Adele Marino, Blanca Bernard-Davila, Maxine S. Jochelson, R. Elena Ochoa-Albiztegui, Danny F. Martinez, Elizabeth A. Morris, Sunitha Thakur and Katja Pinker

    Citation: Breast Cancer Research 2019 21:106

    Content type: Research article

    Published on:

  6. In the USA, the breast cancer mortality rate is 41% higher for African-American women than non-Hispanic White women. While numerous gene expression studies have classified biological features that vary by race...

    Authors: Maya A. Barrow, Megan E. Martin, Alisha Coffey, Portia L. Andrews, Gieira S. Jones, Denise K. Reaves, Joel S. Parker, Melissa A. Troester and Jodie M. Fleming

    Citation: Breast Cancer Research 2019 21:105

    Content type: Research article

    Published on:

  7. Breast cancer remains as one of the most lethal types of cancer in women. Among various subtypes, triple-negative breast cancer (TNBC) is the most aggressive and hard to treat type of breast cancer. Mechanisti...

    Authors: Chinnadurai Mani, Shirisha Jonnalagadda, Jojireddy Lingareddy, Sanjay Awasthi, William H. Gmeiner and Komaraiah Palle

    Citation: Breast Cancer Research 2019 21:104

    Content type: Research article

    Published on:

  8. Solid tumors produce proteins that can induce the accumulation of bone marrow-derived cells in various tissues, and these cells can enhance metastatic tumor growth by several mechanisms. 4T1 murine mammary tum...

    Authors: Momir Bosiljcic, Rachel A. Cederberg, Melisa J. Hamilton, Nancy E. LePard, Bryant T. Harbourne, Jenna L. Collier, Elizabeth C. Halvorsen, Rocky Shi, S. Elizabeth Franks, Ada Y. Kim, Judit P. Banáth, Mark Hamer, Fabio M. Rossi and Kevin L. Bennewith

    Citation: Breast Cancer Research 2019 21:103

    Content type: Research article

    Published on:

  9. Diffusion-weighted imaging (DWI) can increase breast MRI diagnostic specificity due to the tendency of malignancies to restrict diffusion. Diffusion tensor imaging (DTI) provides further information over conve...

    Authors: Jing Luo, Daniel S. Hippe, Habib Rahbar, Sana Parsian, Mara H. Rendi and Savannah C. Partridge

    Citation: Breast Cancer Research 2019 21:102

    Content type: Research article

    Published on:

  10. The incidence of brain metastases in breast cancer (BCBM) patients is increasing. These patients have a very poor prognosis, and therefore, identification of blood-based biomarkers, such as circulating tumor c...

    Authors: Carlotta Riebensahm, Simon A. Joosse, Malte Mohme, Annkathrin Hanssen, Jakob Matschke, Yvonne Goy, Isabell Witzel, Katrin Lamszus, Jolanthe Kropidlowski, Cordula Petersen, Anja Kolb-Kokocinski, Sascha Sauer, Kerstin Borgmann, Markus Glatzel, Volkmar Müller, Manfred Westphal…

    Citation: Breast Cancer Research 2019 21:101

    Content type: Research article

    Published on:

  11. Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall pathologic complete response (pCR) rate of 46%. Dual HER2 blockade wi...

    Authors: Tejal A. Patel, Joe E. Ensor, Sarah L. Creamer, Toniva Boone, Angel A. Rodriguez, Poly A. Niravath, Jorge G. Darcourt, Jane L. Meisel, Xiaoxian Li, Jing Zhao, John G. Kuhn, Roberto R. Rosato, Wei Qian, Anna Belcheva, Mary R. Schwartz, Virginia G. Kaklamani…

    Citation: Breast Cancer Research 2019 21:100

    Content type: Research article

    Published on:

  12. Stromal interaction molecule (STIM) 2 is a key calcium-sensing molecule that regulates the stabilization of calcium ions (Ca2+) and therefore regulates downstream Ca2+-associated signaling and cellular events. We...

    Authors: Yutian Miao, Qiang Shen, Siheng Zhang, Hehai Huang, Xiaojing Meng, Xianchong Zheng, Zhuocheng Yao, Zhanxin He, Sitong Lu, Chunqing Cai and Fei Zou

    Citation: Breast Cancer Research 2019 21:99

    Content type: Research article

    Published on:

  13. Circulating tumor cells (CTCs) represent a temporal “snapshot” of a patient’s cancer and changes that occur during disease evolution. There is an extensive literature studying CTCs in breast cancer patients, a...

    Authors: Vishnu C. Ramani, Clementine A. Lemaire, Melanie Triboulet, Kerriann M. Casey, Kyra Heirich, Corinne Renier, José G. Vilches-Moure, Rakhi Gupta, Aryana M. Razmara, Haiyu Zhang, George W. Sledge, Elodie Sollier and Stefanie S. Jeffrey

    Citation: Breast Cancer Research 2019 21:98

    Content type: Research article

    Published on:

  14. Adjuvant bisphosphonates are associated with improved breast cancer survival in postmenopausal patients. Addition of zoledronic acid (ZA) to neoadjuvant chemotherapy did not improve pathological complete respo...

    Authors: Stefanie de Groot, Hanno Pijl, Ayoub Charehbili, Saskia van de Ven, Vincent T. H. B. M. Smit, Elma Meershoek-Klein Kranenbarg, Joan B. Heijns, Laurence J. C. van Warmerdam, Lonneke W. Kessels, M. Wouter Dercksen, Manon J. A. E. Pepels, Hanneke W. M. van Laarhoven, Birgit E. P. J. Vriens, Hein Putter, Marta Fiocco, Gerrit-Jan Liefers…

    Citation: Breast Cancer Research 2019 21:97

    Content type: Research article

    Published on:

  15. The long time from exposure to potentially harmful chemicals until breast cancer occurrence poses challenges for designing etiologic studies and for implementing successful prevention programs. Growing evidenc...

    Authors: Mary Beth Terry, Karin B. Michels, Julia Green Brody, Celia Byrne, Shiuan Chen, D. Joseph Jerry, Kristen M. C. Malecki, Mary Beth Martin, Rachel L. Miller, Susan L. Neuhausen, Kami Silk and Amy Trentham-Dietz

    Citation: Breast Cancer Research 2019 21:96

    Content type: Review

    Published on:

  16. Breast cancer is a common disease with a relatively good prognosis. Therefore, understanding the spectrum of diseases and mortality among breast cancer patients is important, though currently incomplete. We sy...

    Authors: Haomin Yang, Yudi Pawitan, Wei He, Louise Eriksson, Natalie Holowko, Per Hall and Kamila Czene

    Citation: Breast Cancer Research 2019 21:95

    Content type: Research article

    Published on:

  17. Human epidermal growth factor receptor-2 (HER2)-targeted therapies prolong survival in HER2-positive breast cancer patients. Benefit stems primarily from improved control of systemic disease, but up to 50% of ...

    Authors: Aadya Nagpal, Richard P. Redvers, Xiawei Ling, Scott Ayton, Miriam Fuentes, Elnaz Tavancheh, Irmina Diala, Alshad Lalani, Sherene Loi, Steven David, Robin L. Anderson, Yvonne Smith, Delphine Merino, Delphine Denoyer and Normand Pouliot

    Citation: Breast Cancer Research 2019 21:94

    Content type: Research article

    Published on:

  18. Improving breast cancer survival in sub-Saharan Africa (SSA) is urgently needed, requiring early diagnosis and improved access to treatment. However, data on the types of and barriers to receiving breast cance...

    Authors: Milena Foerster, Benjamin O. Anderson, Fiona McKenzie, Moses Galukande, Angelica Anele, Charles Adisa, Annelle Zietsman, Joachim Schuz, Isabel dos Santos Silva and Valerie McCormack

    Citation: Breast Cancer Research 2019 21:93

    Content type: Research article

    Published on:

  19. This study aimed to develop a prognostic model to predict the breast cancer-specific survival and overall survival for breast cancer patients in Asia and to demonstrate a significant difference in clinical out...

    Authors: Ching-Chieh Huang, Soa-Yu Chan, Wen-Chung Lee, Chun-Ju Chiang, Tzu-Pin Lu and Skye Hung-Chun Cheng

    Citation: Breast Cancer Research 2019 21:92

    Content type: Research article

    Published on:

  20. Women with dense breasts face a double risk for breast cancer; they are at a higher risk for development of breast cancer than those with less dense breasts, and there is a greater chance that mammography will...

    Authors: Olivier Alonzo-Proulx, James G. Mainprize, Jennifer A. Harvey and Martin J. Yaffe

    Citation: Breast Cancer Research 2019 21:91

    Content type: Research article

    Published on:

  21. The presence of tumor-infiltrating lymphocytes (TILs) is correlated with good prognosis and outcome after (immuno)therapy in triple-negative and HER2-positive breast cancer. However, the role of TILs in lumina...

    Authors: Marcelo Sobral-Leite, Izhar Salomon, Mark Opdam, Dinja T. Kruger, Karin J. Beelen, Vincent van der Noort, Ronald L. P. van Vlierberghe, Erik J. Blok, Daniele Giardiello, Joyce Sanders, Koen Van de Vijver, Hugo M. Horlings, Peter J. K. Kuppen, Sabine C. Linn, Marjanka K. Schmidt and Marleen Kok

    Citation: Breast Cancer Research 2019 21:90

    Content type: Research article

    Published on:

  22. Understanding the molecular alterations associated with breast cancer (BC) progression may lead to more effective strategies for both prevention and management. The current model of BC progression suggests a l...

    Authors: Xiaohui Tan, Zhongwu Li, Shuchang Ren, Katayoon Rezaei, Qing Pan, Andrew T. Goldstein, Charles J. Macri, Dengfeng Cao, Rachel F. Brem and Sidney W. Fu

    Citation: Breast Cancer Research 2019 21:89

    Content type: Research article

    Published on:

  23. Trastuzumab is a drug that targets the receptor tyrosine kinase HER2 and is essential for the treatment of HER2-positive breast cancer. Resistance to the drug leads to severe consequences, including disease re...

    Authors: Ami Hori, Masafumi Shimoda, Yasuto Naoi, Naofumi Kagara, Tomonori Tanei, Tomohiro Miyake, Kenzo Shimazu, Seung Jin Kim and Shinzaburo Noguchi

    Citation: Breast Cancer Research 2019 21:88

    Content type: Research article

    Published on:

  24. Approximately two thirds of patients with localized triple-negative breast cancer (TNBC) harbor residual disease (RD) after neoadjuvant chemotherapy (NAC) and have a high risk-of-recurrence. Targeted therapeut...

    Authors: Bradley A. Hancock, Yu-Hsiang Chen, Jeffrey P. Solzak, Mufti N. Ahmad, David C. Wedge, Dumitru Brinza, Charles Scafe, James Veitch, Rajesh Gottimukkala, Walt Short, Rutuja V. Atale, Mircea Ivan, Sunil S. Badve, Bryan P. Schneider, Xiongbin Lu, Kathy D. Miller…

    Citation: Breast Cancer Research 2019 21:87

    Content type: Research article

    Published on:

  25. Circulating tumor cells (CTCs) are important for metastatic dissemination of cancer. They can provide useful information, regarding biological features and tumor heterogeneity; however, their detection and cha...

    Authors: Galatea Kallergi, Vasileia Tsintari, Stelios Sfakianakis, Ekaterini Bei, Eleni Lagoudaki, Anastasios Koutsopoulos, Nefeli Zacharopoulou, Saad Alkahtani, Saud Alarifi, Christos Stournaras, Michalis Zervakis and Vassilis Georgoulias

    Citation: Breast Cancer Research 2019 21:86

    Content type: Research article

    Published on:

  26. Claudin-low breast cancer is a molecular subtype associated with poor prognosis and without targeted treatment options. The claudin-low subtype is defined by certain biological characteristics, some of which m...

    Authors: Christian Fougner, Helga Bergholtz, Raoul Kuiper, Jens Henrik Norum and Therese Sørlie

    Citation: Breast Cancer Research 2019 21:85

    Content type: Research article

    Published on:

  27. Vitamin D has been suggested to prevent and improve the prognosis of several cancers, including breast cancer. We have previously shown a U-shaped association between pre-diagnostic serum levels of vitamin D a...

    Authors: Linnea Huss, Salma Tunå Butt, Signe Borgquist, Karin Elebro, Malte Sandsveden, Ann Rosendahl and Jonas Manjer

    Citation: Breast Cancer Research 2019 21:84

    Content type: Research article

    Published on:

  28. Breast ductal carcinoma in situ (DCIS) represent approximately 20% of screen-detected breast cancers. The overall risk for DCIS patients treated with breast-conserving surgery stems almost exclusively from loc...

    Authors: Sergey Klimov, Islam M. Miligy, Arkadiusz Gertych, Yi Jiang, Michael S. Toss, Padmashree Rida, Ian O. Ellis, Andrew Green, Uma Krishnamurti, Emad A. Rakha and Ritu Aneja

    Citation: Breast Cancer Research 2019 21:83

    Content type: Research article

    Published on:

  29. Non-ER nuclear receptor activity can alter estrogen receptor (ER) chromatin association and resultant ER-mediated transcription. Consistent with GR modulation of ER activity, high tumor glucocorticoid receptor...

    Authors: Eva Tonsing-Carter, Kyle M. Hernandez, Caroline R. Kim, Ryan V. Harkless, Alyce Oh, Kathleen R. Bowie, Diana C. West-Szymanski, Mayra A. Betancourt-Ponce, Bradley D. Green, Ricardo R. Lastra, Gini F. Fleming, Sarat Chandarlapaty and Suzanne D. Conzen

    Citation: Breast Cancer Research 2019 21:82

    Content type: Research article

    Published on:

  30. Mammographic density (MD) is a strong breast cancer risk factor that reflects fibroglandular and adipose tissue composition, but its biologic underpinnings are poorly understood. Insulin-like growth factor bin...

    Authors: Manila Hada, Hannah Oh, Ruth M. Pfeiffer, Roni T. Falk, Shaoqi Fan, Maeve Mullooly, Michael Pollak, Berta Geller, Pamela M. Vacek, Donald Weaver, John Shepherd, Jeff Wang, Bo Fan, Amir Pasha Mahmoudzadeh, Serghei Malkov, Sally Herschorn…

    Citation: Breast Cancer Research 2019 21:81

    Content type: Research article

    Published on:

  31. A large collaborative analysis of data from 47 epidemiological studies concluded that longer duration of breastfeeding reduces the risk of developing breast cancer. Despite the strong epidemiological evidence,...

    Authors: Mustafa M. Basree, Neelam Shinde, Christopher Koivisto, Maria Cuitino, Raleigh Kladney, Jianying Zhang, Julie Stephens, Marilly Palettas, Allen Zhang, Hee Kyung Kim, Santiago Acero-Bedoya, Anthony Trimboli, Daniel G. Stover, Thomas Ludwig, Ramesh Ganju, Daniel Weng…

    Citation: Breast Cancer Research 2019 21:80

    Content type: Research article

    Published on:

  32. Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precisio...

    Authors: Sònia Palomeras, Ángel Diaz-Lagares, Gemma Viñas, Fernando Setien, Humberto J. Ferreira, Glòria Oliveras, Ana B. Crujeiras, Alejandro Hernández, David H. Lum, Alana L. Welm, Manel Esteller and Teresa Puig

    Citation: Breast Cancer Research 2019 21:79

    Content type: Research article

    Published on:

  33. The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer...

    Authors: Yan Xing, Nancy U. Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-MacGregor, Vicente Valero, Sarina A. Piha-Paul, David Hong, Kim-Anh Do, Emily Tarco…

    Citation: Breast Cancer Research 2019 21:78

    Content type: Research article

    Published on:

  34. The effective treatment of triple-negative breast cancer (TNBC) remains a profound clinical challenge. Despite frequent epidermal growth factor receptor (EGFR) overexpression and reliance on downstream signall...

    Authors: Ronan P. McLaughlin, Jichao He, Vera E. van der Noord, Jevin Redel, John A. Foekens, John W. M. Martens, Marcel Smid, Yinghui Zhang and Bob van de Water

    Citation: Breast Cancer Research 2019 21:77

    Content type: Research article

    Published on:

  35. Atypical breast hyperplasias (AH) have a 10-year risk of progression to invasive cancer estimated at 4–7%, with the overall risk of developing breast cancer increased by ~ 4-fold. AH lesions are estrogen recep...

    Authors: Kelly J. Gregory, Amy L. Roberts, Erin M. Conlon, Jacob A. Mayfield, Mary J. Hagen, Giovanna M. Crisi, Brooke A. Bentley, Jeffrey J. Kane, Grace Makari-Judson, Holly S. Mason, Jun Yu, Lihua Julie Zhu, Karl Simin, Jacob P. S. Johnson, Ashraf Khan, Ben R. Schneider…

    Citation: Breast Cancer Research 2019 21:76

    Content type: Research article

    Published on:

  36. Comprehensive breast cancer risk prediction models enable identifying and targeting women at high-risk, while reducing interventions in those at low-risk. Breast cancer risk prediction models used in clinical ...

    Authors: Chang Ming, Valeria Viassolo, Nicole Probst-Hensch, Pierre O. Chappuis, Ivo D. Dinov and Maria C. Katapodi

    Citation: Breast Cancer Research 2019 21:75

    Content type: Research article

    Published on:

    The Letter to this article has been published in Breast Cancer Research 2020 22:35

    The Letter to this article has been published in Breast Cancer Research 2020 22:17

  37. SHC1 proteins (also called SHCA) exist in three functionally distinct isoforms (p46SHC, p52SHC, and p66SHC) that serve as intracellular adaptors for several key signaling pathways in breast cancer. Despite the...

    Authors: Kevin D. Wright, Bradley S. Miller, Sarah El-Meanawy, Shirng-Wern Tsaih, Anjishnu Banerjee, Aron M. Geurts, Yuri Sheinin, Yunguang Sun, Balaraman Kalyanaraman, Hallgeir Rui, Michael J. Flister and Andrey Sorokin

    Citation: Breast Cancer Research 2019 21:74

    Content type: Research article

    Published on:

  38. Neoadjuvant chemotherapy is increasingly given preoperatively to shrink breast tumours prior to surgery. This approach also provides the opportunity to study the molecular changes associated with treatment and...

    Authors: Richard J. Bownes, Arran K. Turnbull, Carlos Martinez-Perez, David A. Cameron, Andrew H. Sims and Olga Oikonomidou

    Citation: Breast Cancer Research 2019 21:73

    Content type: Research article

    Published on:

  39. The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells...

    Authors: David L. Rimm, Gang Han, Janis M. Taube, Eunhee S. Yi, Julia A. Bridge, Douglas B. Flieder, Robert Homer, Anja C. Roden, Fred R. Hirsch, Ignacio I. Wistuba and Lajos Pusztai

    Citation: Breast Cancer Research 2019 21:72

    Content type: Viewpoint

    Published on:

  40. Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regime...

    Authors: Lorenzo Rossi, Chiara Biagioni, Amelia McCartney, Ilenia Migliaccio, Giuseppe Curigliano, Giuseppina Sanna, Erica Moretti, Alessandro M. Minisini, Saverio Cinieri, Carlo Tondini, Grazia Arpino, Antonio Bernardo, Angelo Martignetti, Emanuela Risi, Marta Pestrin, Luca Boni…

    Citation: Breast Cancer Research 2019 21:71

    Content type: Short report

    Published on:

  41. Post-surgery adjuvant radiotherapy (RT) significantly improves clinical outcomes in breast cancer patients; however, some patients develop cancer or treatment-related pain that negatively impacts quality of li...

    Authors: Eunkyung Lee, Omar L. Nelson, Carolina Puyana, Cristiane Takita, Jean L. Wright, Wei Zhao, Isildinha M. Reis, Rick Y. Lin, WayWay M. Hlaing, Johnna L. Bakalar, George R. Yang and Jennifer J. Hu

    Citation: Breast Cancer Research 2019 21:70

    Content type: Research article

    Published on:

  42. The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects of this co...

    Authors: Miguel Quintela-Fandino, Juan V. Apala, Diego Malon, Silvana Mouron, Javier Hornedo, Lucia Gonzalez-Cortijo, Ramon Colomer and Juan Guerra

    Citation: Breast Cancer Research 2019 21:69

    Content type: Research article

    Published on:

  43. Mammographic breast density, adjusted for age and body mass index, and a polygenic risk score (PRS), comprised of common genetic variation, are both strong risk factors for breast cancer and increase discrimin...

    Authors: Celine M. Vachon, Christopher G. Scott, Rulla M. Tamimi, Deborah J. Thompson, Peter A. Fasching, Jennifer Stone, Melissa C. Southey, Stacey Winham, Sara Lindström, Jenna Lilyquist, Graham G. Giles, Roger L. Milne, Robert J. MacInnis, Laura Baglietto, Jingmei Li, Kamila Czene…

    Citation: Breast Cancer Research 2019 21:68

    Content type: Research article

    Published on:

  44. Breast cancer is the second leading cause of cancer deaths in the USA. Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer with high rates of metastasis, tumor recurrence, ...

    Authors: Rachel A. Sabol, Annie C. Bowles, Alex Côté, Rachel Wise, Benjamen O’Donnell, Margarite D. Matossian, Fokhrul M. Hossain, Hope E. Burks, Luis Del Valle, Lucio Miele, Bridgette M. Collins-Burow, Matthew E. Burow and Bruce A. Bunnell

    Citation: Breast Cancer Research 2019 21:67

    Content type: Research article

    Published on:

  45. Acquirement of resistance is always associated with a highly aggressive phenotype of tumor cells. Recent studies have revealed that Annexin A2 (Anxa2) is a key protein that links drug resistance and cancer met...

    Authors: Yanling Fan, Weiyao Si, Wei Ji, Zhiyong Wang, Zicong Gao, Ran Tian, Weijie Song, He Zhang, Ruifang Niu and Fei Zhang

    Citation: Breast Cancer Research 2019 21:66

    Content type: Research article

    Published on:

  46. Heterogeneity and lack of targeted therapies represent the two main impediments to precision treatment of triple-negative breast cancer (TNBC), and therefore, molecular subtyping and identification of therapeu...

    Authors: Pascal Jézéquel, Olivier Kerdraon, Hubert Hondermarck, Catherine Guérin-Charbonnel, Hamza Lasla, Wilfried Gouraud, Jean-Luc Canon, Andrea Gombos, Florence Dalenc, Suzette Delaloge, Jérôme Lemonnier, Delphine Loussouarn, Véronique Verrièle and Mario Campone

    Citation: Breast Cancer Research 2019 21:65

    Content type: Research article

    Published on:

  47. Nicotinamide N-methyltransferase (NNMT) is overexpressed in various human tumors and involved in the development and progression of several carcinomas. In breast cancer, NNMT was found to be overexpressed in seve...

    Authors: Yanzhong Wang, Jin Zeng, Weiping Wu, Shuduo Xie, Haitao Yu, Guoli Li, Tao Zhu, Fengying Li, Jie Lu, Gavin Y. Wang, Xinyou Xie and Jun Zhang

    Citation: Breast Cancer Research 2019 21:64

    Content type: Research article

    Published on:

  48. HER2-driven breast cancer is correlated with poor prognosis, especially during its later stages. Numerous studies have shown the importance of the integrin α3β1 during the initiation and progression of breast ...

    Authors: Veronika Ramovs, Pablo Secades, Ji-Ying Song, Bram Thijssen, Maaike Kreft and Arnoud Sonnenberg

    Citation: Breast Cancer Research 2019 21:63

    Content type: Research article

    Published on:

  49. Environmental and genetic factors play an important role in the etiology of breast cancer. Several small blood-based DNA methylation studies have reported risk associations with methylation at individual CpGs ...

    Authors: Clara Bodelon, Srikant Ambatipudi, Pierre-Antoine Dugué, Annelie Johansson, Joshua N. Sampson, Belynda Hicks, Eric Karlins, Amy Hutchinson, Cyrille Cuenin, Veronique Chajès, Melissa C. Southey, Isabelle Romieu, Graham G. Giles, Dallas English, Silvia Polidoro, Manuela Assumma…

    Citation: Breast Cancer Research 2019 21:62

    Content type: Research article

    Published on:

  50. Glutaminase inhibitors target cancer cells by blocking the conversion of glutamine to glutamate, thereby potentially interfering with anaplerosis and synthesis of amino acids and glutathione. The drug CB-839 h...

    Authors: Maria T. Grinde, Bylgja Hilmarsdottir, Hanna Maja Tunset, Ida Marie Henriksen, Jana Kim, Mads H. Haugen, Morten Beck Rye, Gunhild M. Mælandsmo and Siver A. Moestue

    Citation: Breast Cancer Research 2019 21:61

    Content type: Research article

    Published on:

Annual Journal Metrics

Advertisement